Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).
货号（Catalog No.）
CSD00265
通用名INN
Pateclizumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).
别名(Alternative names)
MLTA3698A,PRO283698,RG7416
靶点;物种(Specificity target name;species)
LTA/TNFSF1[Homo sapiens]
种类(Species)
Humanized
受体鉴定(Receptor identification)
IgG1-kappa
化学信息
CAS
1202526-59-7
存储条件(Storage)
store at -80°C

Note
For research use only. Not suitable for clinical or therapeutic use.